Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. 2018

Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina.

Ovarian cancer is the fifth most common cancer affecting women and at present, stands as the most lethal gynecologic malignancy. The poor disease outcome is due to the nonspecific symptoms and the lack of effective treatment at advanced stages. Thus, it is of utmost importance to understand ovarian carcinoma through several lenses and to dissect the role that the unique peritoneal tumor microenvironment plays in ovarian cancer progression and metastasis. This review seeks to highlight several determinants of this unique tumor microenvironment, their influence on disease outcome and ongoing clinical trials targeting these determinants.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
April 2021, Cancers,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
January 2024, International journal of biological sciences,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
January 2020, Frontiers in cell and developmental biology,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
January 2021, Frontiers in cell and developmental biology,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
December 2023, Journal of ovarian research,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
April 2024, Cancer letters,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
November 2023, International journal of molecular sciences,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
January 2021, Frontiers in oncology,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
April 2024, Clinical and translational medicine,
Alia Ghoneum, and Hesham Afify, and Ziyan Salih, and Michael Kelly, and Neveen Said
September 2013, Frontiers in oncology,
Copied contents to your clipboard!